Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Lyell Immunopharma, Inc. (LYEL) had Free Cash Flow per Share of $-1.76 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.00M |
|
$-24.15M |
|
-- |
|
$0.00M |
|
$44.26M |
|
$-44.26M |
|
$20.11M |
|
$-24.15M |
|
$-24.15M |
|
$-24.15M |
|
$-24.15M |
|
$-24.15M |
|
$-24.15M |
|
$-44.26M |
|
$-42.81M |
|
21.88M |
|
21.88M |
|
$-1.10 |
|
$-1.10 |
|
| Balance Sheet Financials | |
$267.30M |
|
$32.72M |
|
$83.32M |
|
$350.63M |
|
$36.95M |
|
-- |
|
$40.01M |
|
$76.96M |
|
$273.66M |
|
$273.67M |
|
$273.67M |
|
23.33M |
|
| Cash Flow Statement Financials | |
$-38.51M |
|
$17.38M |
|
$51.72M |
|
$61.77M |
|
$92.36M |
|
$30.59M |
|
$4.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2213050.00% |
|
-2213050.00% |
|
-- |
|
-1207650.00% |
|
-1207650.00% |
|
$-38.60M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-8.83% |
|
-8.83% |
|
-6.89% |
|
-8.83% |
|
$11.73 |
|
|
Free Cash Flow per Share |
$-1.76 |
$-1.76 |
|